Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma

Relapsed refractory primary central nervous system lymphoma (R/R PCNSL) has no recognized optimal therapy due to its grave prognosis and high mortality. This report describes a 69-year-old patient with primary central nervous system lymphoma (PCNSL) who rapidly relapsed after achieving complete remission (CR) on first-line treatment and subsequently received treatment with glofitamab to achieve CR again. Grade 1 cytokine release syndrome was observed and there were no fatal side effects. However, limited reports on glofitamab therapy are applied for relapsed and refractory PCNSL. Further <i>ex vivo</i> data demonstrated that glofitamab drove T cell activation and killing ability against lymphoma cells. Our study suggested that glofitamab may be a viable option for relapsed PCNSL patients.